Browse categories and answer follow-up questions to refine your symptom profile.
Approach to the Critical Patient
Immediate stabilization
Resuscitation priorities
Airway compromise from decreased consciousness
If unable to protect airway, rapid sequence intubation
Breathing failure from aspiration or pulmonary edema
If hypoxemia, supplemental oxygen to target SpO2 92-96%
Circulatory instability
If hypotension, isotonic crystalloid 500-1000 mL IV bolus
Active bleeding
If life threatening hemorrhage, massive transfusion protocol consideration
Hyperviscosity recognition triggers
Time critical pattern recognition
Neurologic symptoms
Headache
Confusion
Somnolence
Seizure
Focal neurologic deficit
Visual symptoms
Blurred vision
Diplopia
Visual field loss
Mucosal bleeding
Epistaxis
Gingival bleeding
Easy bruising
Cardiopulmonary symptoms
Dyspnea
Chest discomfort
Heart failure signs
High risk contexts
Known Waldenström macroglobulinemia
Known multiple myeloma
Hyperleukocytosis with acute leukemia
Polycythemia with neurologic or visual symptoms
Monitoring and access
Early monitoring setup
Continuous cardiac monitoring
Dysrhythmia surveillance during electrolyte shifts
Frequent neurologic reassessment
Interval mental status trend
Two large bore IV access
Apheresis compatible access planning
If severe symptoms, arterial line consideration
Frequent blood sampling support
Immediate consultation and activation
Team activation
Hematology urgent consult
Symptomatic suspected paraprotein hyperviscosity
Apheresis service urgent consult
Neurologic symptoms plus suspected paraproteinemia
Visual symptoms plus suspected paraproteinemia
Mucosal bleeding plus suspected paraproteinemia
Oncology consult
Suspected plasma cell dyscrasia or lymphoplasmacytic lymphoma
If hyperleukocytosis, leukemia team consult
Cytoreduction pathway
Early pitfalls to avoid
High risk errors
Red cell transfusion before viscosity control
Potential viscosity increase and neurologic worsening
Diuretics without intravascular assessment
Potential hemoconcentration and viscosity increase
Rituximab initiation before plasmapheresis in Waldenström
IgM flare risk with symptom worsening
Delay in apheresis for classic triad presentation
Time dependent neurologic and visual injury risk
History
Focused symptom pattern
Presenting features
Symptom timing
Rapid progression over hours to days
Neurologic symptoms
Headache
Dizziness
Confusion
Ataxia
Seizure
Visual symptoms
Blurred vision
Transient vision loss
Bleeding symptoms
Epistaxis
Gingival bleeding
Menorrhagia
Constitutional symptoms
Weight loss
Night sweats
Fatigue
Disease specific risk context
Underlying disorder context
Waldenström macroglobulinemia features
Prior IgM paraprotein diagnosis
Peripheral neuropathy
Cryoglobulinemia symptoms
Multiple myeloma features
Bone pain
Recurrent infections
Prior monoclonal gammopathy
Acute leukemia features
Fever
Easy bruising
Dyspnea
Prior blasts or leukocytosis
Polycythemia features
Pruritus after hot shower
Thrombosis history
Medication and exposure factors
Contributing factors
Dehydration
Reduced oral intake
Recent transfusion
Red cell transfusion within days
Prothrombotic medications
Estrogen exposure
Renal impairment
Reduced clearance of paraprotein associated complications
Coding and terminology anchors
Standardized terms
Hyperviscosity syndrome
ICD-10 D75.89 other specified diseases of blood and blood-forming organs
Waldenström macroglobulinemia
ICD-10 C88.0
Multiple myeloma
ICD-10 C90.0
Leukostasis
SNOMED CT concept term leukostasis
Plasma hyperviscosity
SNOMED CT concept term hyperviscosity syndrome
Physical Exam
General and hemodynamics
Initial exam priorities
Mental status
Agitation
Somnolence
Delirium
Vital signs
Hypotension
Tachycardia
Hypoxemia
Volume status
Dry mucous membranes
Poor skin turgor
Bleeding and mucosal findings
Hemorrhage pattern
Epistaxis
Ongoing bleeding
Gingival bleeding
Oozing without trauma
Skin findings
Petechiae
Purpura
Neurologic exam
Neurologic localization
Cranial nerves
Visual acuity change
Dysarthria
Cerebellar function
Ataxia
Motor and sensory
Focal deficit
Seizure activity
Postictal state
Ophthalmologic exam
Funduscopic clues
Retinal hemorrhages
Flame shaped hemorrhages
Venous engorgement
Sausage link segmentation
Papilledema
Optic disc swelling
Pitfalls and mimics on exam
Examination traps
Normal early fundus exam despite symptoms
Need for urgent ophthalmology if visual complaints persist
Focal deficits mimicking stroke
Hyperviscosity related microcirculatory sludging
Differential Diagnosis
Life threatening mimics
Immediate threats
Acute ischemic stroke
Sudden focal deficit
Intracranial hemorrhage
Severe headache
Meningitis or encephalitis
Fever
Status epilepticus
Persistent altered consciousness
Thrombotic thrombocytopenic purpura
MAHA plus thrombocytopenia
Hematologic causes of hyperviscosity phenotype
Viscosity mechanisms
IgM paraproteinemia
Waldenström macroglobulinemia C88.0
IgA paraproteinemia
Multiple myeloma C90.0
IgG paraproteinemia
Multiple myeloma C90.0
Hyperleukocytosis with leukostasis
Acute myeloid leukemia
Acute lymphoblastic leukemia
Erythrocytosis
Polycythemia vera D45
Secondary polycythemia D75.1
Cryoglobulinemia
Cold induced symptoms
Clinical clues to differentiate
Differentiation hints
Mucosal bleeding with retinal findings
Paraprotein hyperviscosity pattern
Dyspnea with very high WBC
Leukostasis pattern
Pruritus and thrombosis history
Polycythemia pattern
Laboratory Tests
Immediate core labs
Initial laboratory bundle
Complete blood count with differential
Hemoglobin and hematocrit for erythrocytosis
Platelet count for bleeding risk modifiers
White blood cell count for hyperleukocytosis
Peripheral blood smear
Rouleaux formation
Circulating blasts
Schistocytes for MAHA screen
Basic metabolic panel
Sodium mmol/L
Potassium mmol/L
Creatinine for renal impairment
Liver panel
Synthetic dysfunction contribution to bleeding
Coagulation studies
INR
aPTT
Fibrinogen
Consumptive coagulopathy assessment
Hyperviscosity targeted labs
Etiology confirmation studies
Serum viscosity
Centipoise value trending with symptoms
Quantitative immunoglobulins
IgM g/L
IgG g/L
IgA g/L
Serum protein electrophoresis
Monoclonal spike identification
Immunofixation
Isotype confirmation
Serum free light chains
Kappa and lambda ratio
Serum albumin and total protein
Protein gap screening
Supportive and complication labs
Complication assessment
Venous blood gas if respiratory compromise
pH
pCO2 mmHg
Lactate mmol/L if shock physiology
Tissue hypoperfusion marker
Type and screen
Transfusion readiness if hemorrhage
Beta hCG in pregnancy risk
Imaging and medication planning
Interpretation pitfalls
Common laboratory pitfalls
Pseudohyponatremia with marked hyperproteinemia
Indirect ISE sodium artifact
Serum viscosity result delay
Clinical diagnosis supported by symptoms and context
Coagulation testing interference
Paraprotein assay artifact consideration
Diagnostic Tests
Scoring Systems
Decision and threshold frameworks
Symptomatic hyperviscosity definition
Neurologic symptoms attributable to impaired microcirculation
Visual symptoms attributable to retinal venous congestion
Mucosal bleeding attributable to paraprotein related platelet dysfunction
Serum viscosity thresholds
Normal serum viscosity approximately 1.4-1.8 centipoise
Symptoms often when viscosity exceeds 4 centipoise
Threshold variability by paraprotein type and patient factors
Paraprotein level risk markers
IgM levels above 40 g/L associated with higher hyperviscosity risk
IgA paraprotein can cause symptoms at lower viscosity than IgG in some patients
Leukostasis risk markers
WBC above 100 x10^9/L high risk for leukostasis
AML leukostasis can occur at lower WBC than ALL
MRI
MRI applications
Brain MRI for persistent neurologic deficit after stabilization
Diffusion restriction for ischemia assessment
Contraindications
Unstable airway or hemodynamics
Interpretation pearls
Multifocal small vessel ischemia pattern support microcirculatory sludging
CT
CT applications
Noncontrast CT head for acute severe headache or focal deficit
Intracranial hemorrhage exclusion
CT angiography head and neck if stroke pathway indicated
Large vessel occlusion assessment
Chest CT if cardiopulmonary symptoms with alternative diagnosis concern
Pulmonary embolism assessment
Pitfalls
Hyperviscosity symptoms can mimic stroke without imaging correlates early
Ultrasound (or US)
Point of care ultrasound uses
Cardiac POCUS for shock
Left ventricular function
Pericardial effusion
Lung ultrasound for dyspnea
B lines for pulmonary edema
Ocular ultrasound if acute visual loss and limited fundoscopy
Vitreous hemorrhage pattern
Vascular ultrasound for suspected thrombosis
Deep vein thrombosis assessment
Disposition
Level of care selection
Disposition targets
ICU admission criteria
Any neurologic symptoms attributed to hyperviscosity
Any visual symptoms attributed to hyperviscosity
Active bleeding requiring ongoing intervention
Hemodynamic instability
Hyperleukocytosis with respiratory or neurologic symptoms
Stepdown admission criteria
Mild symptoms resolved after initial therapy with close monitoring need
Transfer criteria
No on site apheresis capability with symptomatic suspected paraprotein hyperviscosity
No on site leukemia specialty support with leukostasis suspicion
Disposition planning details
System coordination
Early interfacility transfer activation
Apheresis availability confirmation
Hematology accepting service communication
Planned cytoreduction and disease directed therapy timing
Ophthalmology involvement
Retinal hemorrhage or severe visual symptoms
Discharge rarity
Discharge considerations
Asymptomatic hyperproteinemia without hyperviscosity features
Expedited outpatient hematology follow up within 72 hours
Treatment
Supportive care
Immediate supportive measures
Intravascular volume optimization
Isotonic crystalloid 500-1000 mL IV bolus
Repeat bolus based on perfusion and pulmonary status
Stop boluses if pulmonary edema develops
Oxygen support
Nasal cannula oxygen for hypoxemia
Escalate to high flow nasal cannula if persistent work of breathing
Intubation if refractory hypoxemia or inability to protect airway
Seizure management if present
Lorazepam 0.1 mg/kg IV
Maximum 4 mg per dose
Repeat once after 5 minutes if ongoing seizure
Levetiracetam 60 mg/kg IV loading
Maximum 4500 mg
Maintenance 20-30 mg/kg IV every 12 hours
Therapeutic plasma exchange for paraprotein hyperviscosity
Plasma exchange pathway
Indications
Symptomatic hyperviscosity with suspected or confirmed monoclonal gammopathy
Neurologic symptoms
Class I recommendation expert consensus for urgent plasma exchange
Visual symptoms
Class I recommendation expert consensus for urgent plasma exchange
Clinically significant mucosal bleeding
Class I recommendation expert consensus for urgent plasma exchange
Procedure parameters
Exchange volume 1-1.5 plasma volumes per session
Daily sessions until symptom resolution
Goal viscosity reduction with clinical improvement
Replacement fluid 5% albumin
Consider plasma if significant coagulopathy or bleeding
Monitor fibrinogen during repeated exchanges
Timing relative to disease directed therapy
Waldenström macroglobulinemia
Plasma exchange before rituximab initiation
IgM flare risk mitigation
Multiple myeloma
Plasma exchange plus prompt cytoreductive therapy
Hematology directed regimen planning
Transfusion precautions
If severe symptomatic anemia and unstable
Red cell transfusion after plasma exchange when feasible
If transfusion before exchange unavoidable, slow infusion with close neurologic monitoring
Leukostasis and hyperleukocytosis treatment
Leukostasis pathway
Cytoreduction
Hydroxyurea 50 mg/kg/day PO
Divide every 6-12 hours
Titrate daily based on WBC trend and toxicity
Definitive leukemia therapy
Urgent induction planning with hematology
Tumor lysis prophylaxis initiation based on risk
Leukapheresis
Severe symptoms with hyperleukocytosis
Respiratory distress
Class IIa recommendation expert consensus for leukapheresis as adjunct
Neurologic symptoms
Class IIa recommendation expert consensus for leukapheresis as adjunct
Limitations
Temporary WBC reduction without disease control
Not a substitute for chemotherapy
Erythrocytosis driven hyperviscosity
Phlebotomy pathway
Symptomatic polycythemia
Therapeutic phlebotomy 250-500 mL
Repeat to symptom improvement and target hematocrit
Hematology individualized target based on etiology
Volume replacement
Isotonic crystalloid after phlebotomy
Avoid hypotension and hemoconcentration cycles
Bleeding management
Hemorrhage control
Local measures
Topical vasoconstrictor for epistaxis
Tranexamic acid topical or soaked pledget consideration
Avoid if contraindicated by thrombosis concern assessment
Platelet dysfunction from paraprotein
Plasma exchange priority over empiric platelet transfusion when platelets adequate
Platelet transfusion reserved for thrombocytopenia or procedural need
Coagulopathy correction
If fibrinogen low, cryoprecipitate guided by institutional thresholds
Recheck fibrinogen after replacement
Medication cautions
High risk medication decisions
Anticoagulation
Individualized based on thrombosis versus bleeding balance
Hematology input prior to initiation when possible
Diuretics
Avoid early unless clear volume overload
Risk of hemoconcentration and symptom worsening
Special Populations
Pregnancy
Pregnancy specific considerations
Maternal physiology effects
Baseline hypercoagulability
Thrombosis risk amplification with hyperviscosity states
Plasma volume expansion
Symptom expression variability
Diagnostic approach
Beta hCG confirmation
Imaging selection with fetal risk awareness
MRI preferred over CT for neurologic evaluation when stable
Avoid gadolinium unless essential
Treatment considerations
Plasma exchange compatibility with pregnancy
Multidisciplinary coordination with obstetrics
Thromboprophylaxis decisions
Individualized maternal bleeding risk assessment
Geriatric
Older adult considerations
Comorbidity burden
Heart failure vulnerability with aggressive fluids
Frequent lung exam and POCUS reassessment
Medication sensitivity
Sedation risk with benzodiazepines
Lowest effective dose for seizures
Atypical presentations
Delirium as primary manifestation
Lower threshold for hyperviscosity evaluation with paraproteinemia history
Pediatrics
Pediatric considerations
Etiology differences
Leukemia related hyperleukocytosis more common than paraprotein syndromes
Early leukostasis recognition in acute leukemia
Weight based dosing
Hydroxyurea dosing mg/kg/day with hematology oversight
Close monitoring for myelosuppression
Apheresis logistics
Vascular access planning with pediatric anesthesia
Hemodynamic monitoring during exchange
Background
Epidemiology
Epidemiologic patterns
Waldenström macroglobulinemia
Hyperviscosity more common with IgM paraprotein than IgG
Multiple myeloma
Hyperviscosity less common overall but occurs with IgA and high IgG
Acute leukemia
Leukostasis risk increases with hyperleukocytosis
Pathophysiology
Mechanisms of viscosity related injury
Increased plasma viscosity
Paraprotein concentration and molecular size contribution
IgM pentamer high viscosity effect
Impaired microcirculatory flow
Reduced tissue oxygen delivery
Neurologic dysfunction and retinal ischemia
Bleeding tendency
Paraprotein related platelet dysfunction
Mucosal bleeding pattern
Leukostasis
Blast rigidity and endothelial interaction
Pulmonary and CNS microvascular obstruction
Therapeutic Considerations
Treatment rationale
Plasma exchange effectiveness
Rapid reduction in circulating paraprotein
Symptom improvement often within hours
Need for disease directed therapy
Paraprotein production continues without cytoreduction
Recurrence risk without definitive treatment
Transfusion effects
Red cell transfusion increases whole blood viscosity
Timing after viscosity reduction preferred when feasible
Evidence framing
Apheresis recommendations primarily based on expert consensus and observational data
Class I and IIa labels used to reflect consensus strength rather than trial class
Patient Discharge Instructions
copy discharge instructions
Discharge instruction set
Return immediately to emergency care for any new neurologic symptom
Confusion
Weakness
Seizure
Return immediately for any new or worsening vision change
Blurred vision
Vision loss
Return immediately for any uncontrolled bleeding
Nosebleed lasting longer than 20 minutes
Vomiting blood
Black stools
Hydration guidance
Adequate oral fluids unless fluid restricted by clinician
Medication safety
Avoid NSAIDs if bleeding tendency present unless clinician approved
Follow up
Hematology appointment within 72 hours if discharged
Same day return if unable to obtain urgent follow up
References
Clinical guidelines and evidence sources
Reference set
American Society for Apheresis guidelines for therapeutic apheresis indications
Therapeutic plasma exchange for symptomatic paraprotein hyperviscosity
NCCN guidelines Waldenström macroglobulinemia
Rituximab associated IgM flare considerations
International Myeloma Working Group guidance
Acute complications management including hyperviscosity
Acute leukemia supportive care guidance
Hyperleukocytosis and leukostasis cytoreduction strategies
Internal instruction source
Clinical management system formatting and nesting requirements
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.